TITLE

Storm Warnings

AUTHOR(S)
Langreth, Robert; Herper, Matthew
PUB. DATE
March 2006
SOURCE
Forbes Asia;3/13/2006, Vol. 2 Issue 4, p60
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the job cuts in the U.S. pharmaceutical industry as of May 13, 2006. Big pharmaceutical companies such as Johnson & Johnson, Pfizer and Bristol-Myers Squibb have stagnant or declining sales in 2005. The changes could provoking another round of pharmaceutical industry consolidation in the next decade. Only 20 new drugs have reached the market in 2005, a decline from 53 in 1996.
ACCESSION #
20957189

 

Related Articles

  • Has the consolidation wave gone too far? Should the industry consider deconsolidating next? Pajwani, Premal // International Journal of Medical Marketing;Jul2004, Vol. 4 Issue 3, p224 

    This article focuses on the consolidation of the biomedical market. Appetite for mergers and acquisitions in the pharmaceutical industry remains undiminished some 15 years after consolidation first began. Starting with the 1989 mergers of Bristol Myers with Squibb and SmithKline with Beecham...

  • Decades of Change for the Top Pharmaceutical Companies. Van Arnum, Patricia // Pharmaceutical Technology;Jul2012, Vol. 36 Issue 7, p54 

    The article focuses on the change of the top pharmaceutical companies in 2012, which center on drug prescription. It says that Merck & Co. was ranked as the number one company in the sale of drugs prescription, followed by Bristol-Myers Squibb Co. due to the merger between Bristol-Myers and...

  • Pharmaceutical companies work to stabilize bottom line. Martinez, Marialba // Caribbean Business;7/4/2002, Vol. 30 Issue 27, p16 

    Reports on strategies used by U.S. pharmaceutical companies to strengthen their stock prices. Plan of Pfizer Inc. to buy back its common stock; Stock repurchase program approved by the board of Johnson and Johnson; Bristol-Myers Squibb's sale of its Clairol beauty unit; Joint venture announced...

  • Global Pharmaceuticals.  // Pharmaceuticals Industry Profile: Global;January 2003, pN.PAG 

    Presents a profile of the Pharmaceuticals industry in Global. Background on Datamonitor, a business information company specializing in industry analysis; Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the...

  • Pharmaceuticals Industry Profile: Canada.  // Pharmaceuticals Industry Profile: Canada;Dec2005, p1 

    Presents a profile of the Pharmaceuticals industry in Canada. Background on Datamonitor, a business information company specializing in industry analysis; Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the...

  • Pharmaceuticals in the United States.  // Pharmaceuticals Industry Profile: United States;January 2003, pN.PAG 

    Presents a profile of the Pharmaceuticals industry in the United States. Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the industry; Market forecasts; Demographics; Further reading.

  • Pharmaceuticals Industry Profile: United States.  // Pharmaceuticals Industry Profile: United States;Dec2005, p1 

    Presents a profile of the Pharmaceuticals industry in the United States. Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the industry; Market forecasts; Demographics; Further reading.

  • Mixed Fortunes and Scrutiny For Bristol-Myers Squibb and J&J. Mirasol, Feliza // Chemical Market Reporter;10/11/2004, Vol. 266 Issue 12, p13 

    Examines the fortunes and scrutiny for drug companies Bristol-Myers Squibb Co. (BMS) and Johnson & Johnson (J&J) Inc., respectively, in the United States. Approval of BMS's antischizophrenia product Abilify; Total revenue for Abilify; Marketing snag over J&J's anti-anemia drug Procrit.

  • BMS Gets Fibrosis Program in Potential $475M Amira Buy. Boggs, Jennifer // BioWorld Today;7/25/2011, Vol. 22 Issue 142, p1 

    This article reports on the plan of Bristol-Myers Squibb Co. (BMC) to acquire Amira Pharmaceuticals Inc. in 2011. BMC will acquire the pharmaceutical firm for 375 million U.S. dollars in cash. The deal will include the firm's lysophosphatidic acid 1 (LPA1) receptor antagonist AM152. Shareholders...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics